PharmiWeb.com - Global Pharma News & Resources
23-Feb-2026

ErVimmune

ALA has recently collaborated with ErVimmune, a French preclinical biotechnology company developing next-generation cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that don’t repond to current immunotherapies, to announce a €17M Series A funding.

Editor Details

Last Updated: 23-Feb-2026